Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Closets for Your Room: Plan and Utility Features06.06.2024 - 2The most effective method to Explore Moral Situations in Brain research with Your Certification17.10.2023
- 3Electric discovery on Mars! Scientists find tiny lightning bolts coming from Red Planet dust clouds01.12.2025
- 4Criminal Guard Lawyer Expenses: What Would it be advisable for you to Hope to Pay?30.06.2023
- 5A definitive Manual for Internet Mastering and Expertise Improvement01.01.1
- 10 Activities to Lift Your Consume and Bust Your Stomach
- Santa's sleigh or the International Space Station? How to spot a bright Christmas flyby Dec. 24 and 25
- Saturn shines with the waxing moon at sunset on Nov. 29
- I binged all 24 Hallmark Christmas movies in less than 30 days. I emerged a changed man.
- Nikki Glaser returns as host of the 2026 Golden Globes: Everything the comedian has said about the upcoming awards show
- Federal judge upholds Hawaii's new climate change tax on cruise passengers
- Aluminum salts emerge as likely target as health officials scrutinize childhood vaccines
- Wedding trip Objections in the US
- Protest inspired by 'Gen Z' movement draws few young people in Mexico and many government critics
